NovaBay Pharmaceuticals, Inc.
NBY
$1.03
$0.4371.67%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 2.31M | 2.42M | 2.39M |
| Total Other Revenue | -- | -- | -3.00K | 17.00K | 13.00K |
| Total Revenue | -- | -- | 2.31M | 2.44M | 2.40M |
| Cost of Revenue | -- | -- | 807.00K | 848.00K | -- |
| Gross Profit | -- | -- | 1.50M | 1.59M | -- |
| SG&A Expenses | 1.89M | 2.70M | 2.78M | 2.65M | 1.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.89M | 2.70M | 3.60M | 3.50M | 1.62M |
| Operating Income | -1.89M | -2.70M | -1.29M | -1.06M | -1.62M |
| Income Before Tax | -1.96M | -3.33M | -1.32M | -1.21M | -2.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.96M | -3.33M | -1.32M | -1.21M | -2.15M |
| Earnings from Discontinued Operations | 42.00K | 11.00M | 111.00K | -- | 564.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.92M | 7.67M | -1.21M | -1.21M | -1.59M |
| EBIT | -1.89M | -2.70M | -1.29M | -1.06M | -1.62M |
| EBITDA | -1.89M | -2.70M | -1.28M | -1.05M | -1.61M |
| EPS Basic | -0.33 | 1.45 | -0.15 | -0.60 | -1.37 |
| Normalized Basic EPS | -0.21 | -0.32 | -0.10 | -0.20 | -1.12 |
| EPS Diluted | -0.33 | 1.45 | -0.15 | -0.60 | -1.37 |
| Normalized Diluted EPS | -0.21 | -0.32 | -0.10 | -0.20 | -1.12 |
| Average Basic Shares Outstanding | 5.82M | 5.31M | 8.00M | 3.71M | 1.16M |
| Average Diluted Shares Outstanding | 5.82M | 5.42M | 8.00M | 3.71M | 1.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |